Scinai Immunotherapeutics Ltd 6-K, filed Sep 22, 2023
Scinai Immunotherapeutics Ltd. (SCNI)
About this 6-K
Scinai Immunotherapeutics Ltd filed this 6-K on September 22, 2023.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
For the Month of September 2023
Commission File Number: 001-37353
SCINAI IMMUNOTHERAPEUTICS LTD.
(Translation of registrant’s name into English)
Jerusalem BioPark, 2nd Floor
Hadassah Ein Kerem Campus
Jerusalem, Israel
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Scinai Immunotherapeutics Ltd. (the “Company”) has made available an updated presentation about its business, a copy of which is furnished herewith as Exhibit 99.1 and incorporated by reference. The presentation includes, among others, updated select financial and cap table information. The new updates in the presentation are not an admission as to the materiality of any information therein. The information contained in the presentation is summary information that should be considered in the context of the Company’s filings with the Securities and Exchange Commission and other public announcements the Company may make by press release or otherwise from time to time.
Exhibit Index
| Exhibit No. | Description | |
| 99.1 | Scinai Immunotherapeutics Presentation dated September 2023 |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Scinai Immunotherapeutics Ltd. | ||
| Date: September 22, 2023 | By: | /s/ Amir Reichman |
| Amir Reichman | ||
| Chief Executive Officer | ||
2
Exhibit 99.1
• • • • • • • •
• • • • • • • • • • •
10 15 20 30 25 40 70 60 50 85 100 Y ea s t: P i chi a pas t or i s
• • • • • • • • • • •
• • • • •
• • • • • • • • •
• • • • • • • • • • • • • •
IL - 17 is a cytokine that plays a key role in the development of psoriatic lesions, which are in essence an acute, local (dermis) flareup of a chronic underlying disease . It allows for local (rather than systemic) administration of anti – IL - 17 drugs to stop the cytokine cascade .
• • • • • •
• • • • •
• • • Image source: https:// www.researchgate.net/publication/272185735_Three - Dimensional_Skin_Models_of_Psoriasis
ц
• • • • • • •
Píesence of Psoíiasin (S100A7) in an InflammaSkin Model with ľ - Cell activation No induction ľ - cell activation leads to significant incíease in IL - 17A expíession • healthy ex vivo skin samples of one donoí, gíowing in a well • •
• •
• • •
• •
• - - • - • - • • • • • • • •
10 1 10 2 10 3 10 4 10 5 10 6 Titer [TCID 50 /g] limit of detection ٓٓٓٓ ٓٓٓٓ ٓٓٓٓ ٓٓٓٓ 9 8 7 6 5 4 3 2 1 SARS - CoV - 2 RNA copies/ml BALF ٓٓ ٓٓٓٓ ٓ ٓٓ de t e c t i o n limit
• • • • • • • •
• • •
• •
• • • • • •
